In this regard, glucose-lowering drugs, including SGLT2 inhibitors or glucagon-like peptide 1 receptor agonists (GLP-1 RAs) that confer protection against major cardiovascular diseases, are promising for preventing HF in NAFLD or MAFLD [46]. Here, SLC5A2 is linked to metabolic dysfunction-associated steatotic liver disease.